Fig. 1.
Static Physician’s Global Assessment (sPGA) and patient global assessments (PtGA) among patients with psoriasis treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks. PtGA: †p < 0.01, ‡p < 0.001 UST vs IXE; sPGA: **p < 0.01, ***p < 0.001 UST vs IXE. p-values derived from Wilcoxon rank sum test. mBOCF: modified baseline-observation carried forward.
